NTRK fusion positive cancer
MONDO:0700215Neoplasm associated with the expression of a Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion. NTRK fusion-positive tumors have been identified in a broad range of solid tumor types, including breast, cholangiocarcinoma, colorectal, gynecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma and thyroid cancers.
Also known as: NTRK fusion positive neoplasm, NTRK fusion positive solid tumor, NTRK fusion positive solid tumour, neurotrophic tyrosine receptor kinase fusion positive cancer, neurotrophic tyrosine receptor kinase fusion positive neoplasm, neurotrophic tyrosine receptor kinase fusion positive solid tumor, neurotrophic tyrosine receptor kinase fusion positive solid tumour
1450 clinical trials for this condition and its sub-types, 19 tagged with NTRK fusion positive cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for kids with tough cancers: entrectinib trial underway
Disease control OngoingThis study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Scientists dig into the DNA of drug-resistant lung cancers to find hidden clues
Knowledge-focused By invitation onlyThis study enrolls 40 people with non-small cell lung cancer whose tumors have stopped responding to targeted therapy (tyrosine kinase inhibitors). Researchers will analyze the tumors' full genetic code and RNA to find new resistance mechanisms. The goal is to better understand w…
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC